Project "Primary Cell Gut-on-Chip Model for Evaluating the Effect of Orally Administered Medications on Intestinal Stem Cells" has received Pharmaceutical, Biomedical, and Medical Technology Competence Center (FBMTKC) funding. Our project's aim is to develop a vascularized gut-on-chip model from primary cells using Cellbox Labs technology and compare the effects of tamoxifen in this biological model with well-documented clinical data. This approach will enable more effective testing of the impact of such medications on the gut and their ability to enter the bloodstream in preclinical studies before further testing on animals and clinical trials. As a result, it will save time and resources in drug development processes and facilitate the delivery of more effective oral medications with fewer side effects to patients.

‍